3 Kapital suchende Unternehmen Unternehmensprofile - Deutsches ...

Scil Proteins GmbH
Biotechnologie
Profil
Jahr der Gründung
Mitarbeiter
Eigenkapital (in m EUR)
Kapital Bedarf (in m EUR)
Positives Ergebnis seit
Umsatz 2009 (in m EUR)
Umsatz 2010e (in m EUR)
Umsatz 2011e (in m EUR)
Kontakt
Ansprechpartner
Telefon
Fax
E-Mail
Web
Adresse
2000
100
2
25
2013
k.A.
k.A.
k.A.
Dr. Ulrike Fiedler
+49-(0) 3 45-27 99 63 31
+49-(0) 3 45-27 99 63 32
ulrike.fiedler@scilproteins.com
www.scilproteins.com
Heinrich-Damerow-Strasse 1
06120 Halle (Saale)
Deutschland
3 / 46
Geschäftsfeld
Scil Proteins is a biopharmaceutical company whose key value
driver is its proprietary Affilin drug discovery platform.
Scil Proteins has longstanding expertise in protein manufacturing.
the certified GMP production facility generates revenue
through long term customer contracts.
The Affilin scaffold technology platform is a unique tool that
rapidly generates multiple new drug candidates, satisfying the
need for the pharmaceutical industry to fill pipelines. It is based
on a strong and undisputed patent estate.
Affilin therapeutics have competitive advantages over small molecules,
antibodies and other scaffold approaches. Based on a
unique mechanism of action,selected Affilin conjugates provides
treatments with low side effects , enabling the development of
novel treatments.
Strategische Marktposition
The business model capitalizes on the current dearth of clinical
candidates throughout the industry, the high prices for Phase I/
II compounds and the increasing outsourcing of manufacturing
activities.
Management
CEO: Dr. Ulrike Fiedler, co founder of the company; CFO: Frank
Ubags, former Rhein Biotech and Kiadis Pharma;CSO: Dr. Arnd
Steuernagel, former Develogen;CBO: Dr. Henning Afflerbach, former
Direvo
Beabsichtigte Investition/Zusätzliche Informationen
Financing Need € 25-30 million
Shareholder: BioNetventures, 100%